Trends in Mode of Hysterectomy After the US Food and Drug Administration Power Morcellation Advisory

被引:42
|
作者
Ottarsdottir, Helga
Cohen, Sarah L.
Cox, Mary
Vitonis, Allison
Einarsson, Jon I.
机构
[1] Brigham & Womens Hosp, Div Minimally Invas Gynecol Surg, 75 Francis St, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Dept Obstet & Gynecol, Epidemiol Ctr, 75 Francis St, Boston, MA 02115 USA
来源
OBSTETRICS AND GYNECOLOGY | 2017年 / 129卷 / 06期
关键词
D O I
10.1097/AOG.0000000000002058
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: To evaluate the trends in mode of surgery for benign hysterectomy after the 2014 U.S. Food and Drug Administration (FDA) morcellation guidelines. METHODS: This is a retrospective review of all patients who underwent a hysterectomy for benign indications, specifically for leiomyomas, at Brigham and Women's Hospital from 2013 to 2015. The rates of abdominal, vaginal, laparoscopic, and robotic-assisted laparoscopic hysterectomy as well as the perioperative outcomes were compared over the study period. Analysis was performed using multi-variable linear, multinomial, and logistic regression. Regression models were adjusted for potential confounders. RESULTS: From 2013 to 2015, 1,530 patients underwent a hysterectomy for benign indications and 639 patients underwent the procedure for the indication of uterine leiomyomas; there was a decrease in the number of hysterectomy cases in the later years. Focusing on the patients with leiomyomas alone, there was a 40-60% decreased odds of a minimally invasive procedure in 2014 or 2015 compared with 2013 [adjusted odds ratio (OR) 0.53 (0.29-0.97) in 2014 and adjusted OR 0.40 (0.22-0.74) in 2015, P=.003]. A 24% decrease in the supracervical approach to hysterectomy was also noted. Despite these trends, the majority of cases in each year were still performed in a minimally invasive fashion. The factor most strongly associated with undergoing a minimally invasive hysterectomy was having a fellowship-trained surgeon perform the procedure [adjusted OR 6.80 (3.65-12.7), P<.001]. There was no significant difference between the year of surgery and occurrence of intraoperative complications or reoperation. CONCLUSION: Although key perioperative outcomes remained similar, the overall rate of minimally invasive surgery declined at our institution after the FDA's recommendations. With changing practice patterns and vigilance surrounding power morcellation, gynecologic surgeons may still offer patients minimally invasive procedures with all of the accompanying advantages.
引用
收藏
页码:1014 / 1021
页数:8
相关论文
共 50 条
  • [1] Trends in Hysterectomy After Cessation of Power Morcellation
    Susla, Lyudmyla
    Brown, Amy
    Einstein, Margaret
    O'Sullivan, David
    Shafer, Aaron
    [J]. OBSTETRICS AND GYNECOLOGY, 2017, 129 : 87S - 87S
  • [2] Changes in Myomectomy Practice After the US Food and Drug Administration Safety Communication on Power Morcellation
    Stentz, Natalie C.
    Cooney, Laura G.
    Sammel, Mary
    Shah, Divya K.
    [J]. OBSTETRICS AND GYNECOLOGY, 2017, 129 (06): : 1007 - 1013
  • [3] Association of the US Food and Drug Administration Morcellation Warning With Rates of Minimally Invasive Hysterectomy and Myomectomy
    Barron, Kenneth I.
    Richard, Tere
    Robinson, Patricia S.
    Lamvu, Georgine
    [J]. OBSTETRICS AND GYNECOLOGY, 2015, 126 (06): : 1174 - 1180
  • [4] Practice patterns and postoperative complications before and after US Food and Drug Administration safety communication on power morcellation
    Harris, John A.
    Swenson, Carolyn W.
    Uppal, Shitanshu
    Kamdar, Neil
    Mahnert, Nichole
    As-Sanie, Sawsan
    Morgan, Daniel M.
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2016, 214 (01) : 98.e1 - 98.e13
  • [5] Temporal trends in minimally invasive myomectomy before and after the US Food and Drug Administration recommendation against electric morcellation
    Pereira, Nigel
    Frankel, William C.
    Hutchinson, Anne P.
    Patel, Hency H.
    Mostisser, Cheri
    Elias, Rony T.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2017, 137 (03) : 295 - 300
  • [6] Public Awareness of Uterine Power Morcellation Through US Food and Drug Administration Communications: Analysis of Google Trends Search Term Patterns
    Wood, Lauren N.
    Jamnagerwalla, Juzar
    Markowitz, Melissa A.
    Thum, D. Joseph
    McCarty, Philip
    Medendorp, Andrew R.
    Raz, Shlomo
    Kim, Ja-Hong
    [J]. JMIR PUBLIC HEALTH AND SURVEILLANCE, 2018, 4 (02): : 82 - 86
  • [7] US Food and Drug Administration's Guidance Regarding Morcellation of Leiomyomas
    Parker, William H.
    Kaunitz, Andrew M.
    Pritts, Elizabeth A.
    Olive, David L.
    Chalas, Eva
    Clarke-Pearson, Daniel L.
    Berek, Jonathan S.
    [J]. OBSTETRICS AND GYNECOLOGY, 2016, 127 (01): : 18 - 22
  • [8] Google searches and medical publication trends since the 2014 US Food and Drug Administration position on power morcellation: Do these translate into patient awareness?
    Liou, N. S.
    Mallick, R.
    Aref-Adib, M.
    Odejinmi, F.
    [J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2019, 243 : 168 - 172
  • [9] Impact of the 2014 Food and Drug Administration Warnings Against Power Morcellation
    Lum, Deirdre A.
    Sokol, Eric R.
    Berek, Jonathan S.
    Schulkin, Jay
    Chen, Ling
    McElwain, Cora-Ann
    Wright, Jason D.
    [J]. JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY, 2016, 23 (04) : 548 - 556
  • [10] The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process
    Roden, DM
    Temple, R
    [J]. CIRCULATION, 2005, 111 (13) : 1697 - 1702